Caspase 3 expression is also decreased in the tissues of patients determined to have higher-grade prostate cancer associated with apoptosis resistance in CRPC [36,37] Thus, nanaomycin K’s therapeutic mechanism of action may involve decreasing Erk1/2 and increasing Caspase 3. This evidence concerns the gene MAPK3 and prostate carcinoma.